PFE Jan 2024 47.000 call
| Previous close | 1.1400 |
| Open | 1.2000 |
| Bid | 1.2200 |
| Ask | 1.3100 |
| Strike | 47.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.1100 - 1.2600 |
| Contract range | N/A |
| Volume | |
| Open interest | 7.73k |
- Motley Fool
3 Surprisingly Underrated Stocks to Buy in April
Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE) as opportunities that especially stand out. Prosper Junior Bakiny (Axsome Therapeutics): Last year, Axsome Therapeutics' share price doubled, partly due to the FDA approving its depression medicine Auvelity for use. The company's stock is down by 19% since the start of the year.
- Motley Fool
If You Invested $25,000 in Pfizer in 2020, This Is How Much You Would Have Today
Investing in top COVID-19 vaccine maker Pfizer (NYSE: PFE) seems like it should have made you rich if you bought the stock in March 2020. On March 2, 2020, Pfizer's stock was selling for $33 a share. It would be nearly a year before Pfizer had an approved COVID-19 vaccine, which was produced in partnership with BioNTech.
- Motley Fool
Is It Time to Buy These Ultra-Cheap Dividend Stocks?
High-quality dividend stocks can be a great way to tilt the odds in your favor as an investor. The core reason is that top-shelf dividend stocks generally have a long-standing shareholder base due to the reliability of their payouts.
